Dermatologists building the future of pattern hair loss treatment

Dr. Waldman is the Chief Executive Officer (CEO) of Veradermics. Under his stewardship, he has positioned Veradermics for rapid growth by implementing a differentiated strategy centered on advancing first-in-class therapeutics for under-innovated markets in aesthetics and dermatology.

He has also successfully led the company through significant equity financings, and has advanced Veradermics lead asset, VDPHL01, a potential non-hormonal oral treatment for pattern hair loss, into Phase 3 trials. Dr. Waldman is a board-certified dermatologist with more than 10 years of clinical experience. Prior to founding Veradermics, Dr. Waldman was a prolific researcher authoring more than 100 publications including a textbook titled, “Dermatology for the Primary Care Provider.” He has been the recipient of numerous accolades including the American Academy of Dermatology’s “Excellence in Patient Care” award. He earned his BA and his MD degrees from the University of Missouri-Kansas City 6 Year BA/MD Program and completed his dermatology residency with a “Distinction in Clinical Trials” at the University of Connecticut.

Dr. Durso is the Chief Technical Officer of Veradermics. He heads research and development for the company and serves as the primary medical expert for clinical operations. Since the company’s founding, he has successfully advanced ideas on paper into late-stage clinical testing including the company’s lead asset, VDPHL01, a non-hormonal oral therapeutic for the treatment of pattern hair loss currently in Phase 3 clinical trials.

Dr. Durso is a board-certified dermatologist by training with more than 10 years of clinical experience. He is a recognized expert in innovation for both drug and device domains within the field of dermatology having authored a number of peer-reviewed articles and book chapters on a variety of dermatologic subjects. He has also been awarded national recognition for his work including being named a Resident of Distinction by the DermMentors Foundation and a past Grand Prize Winner of MIT Hacking Dermatology. His educational background includes a Bachelor of Science degree magna cum laude from the University of Notre Dame and his Medical Degree summa cum laude from Loyola University Chicago.

Dominic Carrano is the Chief Financial Officer (CFO) of Veradermics, with over 15 years of experience in financial leadership, technical accounting, and strategic planning in the life sciences sector. He leads the company’s financial strategy and operations to support growth and execution.

Prior to becoming CFO, Mr. Carrano served as Vice President of Finance at Veradermics, where he oversaw financial operations and financing activities. Before that, he was Vice President of Finance and Controller at Rallybio Corporation, where he led financial operations and played a key role in the company’s IPO execution, follow-on offering, and ongoing SEC compliance.

Mr. Carrano began his career at Deloitte & Touche LLP and later held financial leadership roles at Alexion Pharmaceuticals, focusing on SEC reporting and technical accounting.

He holds both a MS and a BS in Accounting from the University of Connecticut and is a Certified Public Accountant.

Mark Neumann brings more than three decades of biopharmaceutical commercial leadership, most recently serving as Executive Vice President and Chief Commercial Officer at Intra-Cellular Therapies (ITCI), where he built the commercial function from its inception and led the successful commercialization and launch of CAPLYTA®. He played a central role in guiding investor engagement and strategic planning, and his leadership was instrumental in ITCI’s $14.6B acquisition by Johnson & Johnson in 2025.

Prior to ITCI, Mr. Neumann held senior leadership roles at Amgen, overseeing global franchise strategy and commercialization planning across three major therapeutic areas. He also led the launch of Amgen’s first U.S. cardiovascular business unit, introducing REPATHA, in a challenging payer environment and achieving category leadership.

Earlier in his career, Mr. Neumann had a long tenure at Bristol-Myers Squibb (BMS), where he held a range of domestic and global roles. These included serving as the global brand lead for ELIQUIS, developed & commercialized in partnership with Pfizer; heading sales and marketing for ABILIFY in collaboration with Otsuka; and leading a U.S. diabetes field organization under a joint venture with AstraZeneca. He also directed national marketing efforts for cardiovascular products, including PLAVIX and PRAVACHOL, managing co-commercialization partnerships with Sanofi.

Mr. Neumann’s experience building commercial organizations from the ground up, launching blockbuster therapies, and leading integrated DTC and HCP marketing initiatives will be critical to the commercial development of VDPHL01.

Michael Greco, JD serves as General Counsel of Veradermics. He brings deep experience advising publicly traded and growth-stage biopharmaceutical companies, having previously served as General Counsel and Secretary of Rallybio Corporation and SpringWorks Therapeutics, Inc. Earlier in his career, Mr. Greco spent several years at Alexion Pharmaceuticals, Inc., where he held roles of increasing responsibility within the legal department, ultimately serving as Senior Vice President of Law and Corporate Secretary. Prior to his in-house leadership roles, he practiced as a corporate and transactional attorney at Bingham McCutchen LLP (now Morgan, Lewis & Bockius LLP) and Wiggin and Dana LLP. He earned his J.D. from Suffolk University Law School and a B.S. from the United States Military Academy at West Point.

Dr. David A. Hollander is the Chief R&D Officer of Veradermics, where he oversees clinical development, regulatory affairs, quality, and CMC. He joined the company in August 2026 after serving as Chief Medical Officer and Global Therapeutics Commercial Lead at Revance Therapeutics. There, he led the clinical development and global regulatory approvals of DAXXIFY® across aesthetics and neurology, as well as the U.S. therapeutics launch for cervical dystonia.

Previously, Dr. Hollander served as Chief R&D Officer at Aerie Pharmaceuticals, where he led the early development of acoltremon, a first-in-class treatment for dry eye. He began his industry career at Allergan and advanced through senior roles in medical affairs and clinical development, including Vice President and Global Head of Eye Care for Medical Affairs and Therapeutic Area Head for Anterior Segment and Consumer Eye Care. During this time, he continued to see patients and teach residents at UCLA, where he received a faculty teaching award. He has served on the board of Kiora Pharmaceuticals since 2021.

Dr. Hollander earned a Bachelor of Science in Chemistry with honors and distinction from Stanford University, a medical degree from the University of Pennsylvania, and an M.B.A. in Health Care Management from the Wharton School. He completed his ophthalmology residency at UCSF and a Heed Fellowship in Cornea, External Disease and Refractive Surgery at UCLA’s Jules Stein Eye Institute. He has authored more than 90 peer-reviewed scientific publications and has lectured nationally and internationally on regulatory endpoint selection and collaboration between academia and industry.